Below is a comprehensive archive of press releases from MSF-USA. Use the options in the boxes below to filter results based on your preferences.

Country/Region

April 27, 2016

MSF hands over global petition as volunteers place 2,500 flowers in front of Pfizer’s headquarters in New York, representing the number of kids who die of pneumonia each day.

April 12, 2016

More than fifty groups have come together to demand that the US Congress reject the Trans-Pacific Partnership Trade Deal (TPP) due to provisions it contains that would undermine public health. In a letter sent to Congress today, the groups outlined the damaging effects the trade deal would have on public health, and said lawmakers should not vote for the TPP unless damaging provisions are removed.

March 18, 2016

Statement by Judit Rius Sanjuan, Doctors Without Borders/Médecins Sans Frontières’ (MSF) US Access Campaign Manager and Legal Policy Adviser 

March 10, 2016

Judit Rius Sanjuan, Access Campaign manager & legal policy advisor at Doctors Without Borders/Médecins Sans Frontières (MSF), made the following statement after KaloBios Pharmaceuticals obtained bankruptcy court permission to keep pursing a drug that could receive a US Federal Drug Administration Priority Review Voucher (PRV).

March 09, 2016

New York— A Senate committee voted today to add Zika to the list of diseases eligible for the US Federal Drug Administration (FDA) Priority Review Voucher (PRV) program for neglected diseases, but did not fix major loopholes that make the PRV program for neglected diseases ripe for abuse by pharmaceutical companies.

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

February 03, 2016

New YorkAs representatives from the United States and 11 other Pacific Rim countries gather in New Zealand Thursday to sign the Trans-Pacific Partnership (TPP) trade agreement, the fight to protect access to medicines in TPP countries is intensifying at the national level, with legislative processes starting that will determine if the deal is finally ratified and implemented.

January 12, 2016

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is gravely concerned about the impact that the Trans-Pacific Partnership (TPP) will have on access to medicines around the world. In his comments on the TPP tonight, the President continued to promote a trade deal that will export the policies that have made medicines unaffordable in the US to close to half a billion people around the world.

December 09, 2015

WASHINGTON, D.C., DECEMBER 9, 2015 — The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today delivered a petition signed by more than 547,000 people to the White House, calling for President Obama to consent to an independent investigation of the deadly U.S. airstrikes on MSF's trauma hospital in Kunduz, Afghanistan.

Pages